分析孟鲁司特钠治疗小儿反复发作性过敏性紫癜的临床疗效  

Analysis of the clinical efficacy of montelukast sodium in the treatment of recurrent allergic purpura in children

作　　者：朱爱红 ZHU Ai-hong(Xuzhou Tongshan District People's Hospital, Xuzhou 221000, China)

机构地区：[1]徐州市铜山区人民医院儿科,221000

出　　处：《中国实用医药》2019年第10期77-78,共2页China Practical Medicine

摘　　要：目的分析孟鲁司特钠治疗小儿反复发作性过敏性紫癜(AP)的临床疗效。方法 42例AP患儿,随机分为对照组和治疗组,各21例。对照组采用抗过敏、饮食干预等常规治疗,治疗组在常规基础上采用孟鲁司特钠治疗,比较两组临床疗效、复发情况、不良反应发生情况及治疗前后尿生化指标[免疫球蛋白G(IgG)、转铁蛋白(TRF)及微量白蛋白(Alb)]。结果治疗组总有效率为90.48%,复发率为4.76%;对照组总有效率为61.90%,复发率为28.57%;治疗组总有效率高于对照组,复发率低于对照组,差异有统计学意义(P<0.05)。治疗前两组IgG、TRF及Alb比较差异无统计学意义(P>0.05);治疗后观察组IgG、TRF及Alb均明显低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率14.29%与对照组的9.52%比较,差异无统计学意义(P>0.05)。结论对反复发作的AP患儿给予孟鲁司特钠治疗,可有效改善尿生化指标,提升临床疗效。Objective To analyze the clinical efficacy of montelukast sodium in the treatment of recurrent allergic purpura(AP) in children. Methods A total of 42 AP children were randomly divided into control group and treatment group, with 21 cases in each group. The control group was treated with conventional therapy of anti-allergy and dietary intervention, and the treatment group was treated with montelukast sodium on the basis of conventional therapy. Comparison were made on clinical efficacy, recurrence, occurrence of adverse reactions, and urine biochemical indicators [immunoglobulin G(IgG), transferrin(TRF) and Microalbumin(Alb)] before and after treatment between the two groups. Results The treatment group had total effective rate as 90.48% and recurrence rate as 4.76%, which were 61.90% and 28.57% in the control group. The treatment group had higher total effective rate than the control group, and lower recurrence rate than the control group. Their difference was statistically significant(P<0.05). Before treatment, both groups had no statistically significant difference in IgG, TRF and Alb(P>0.05). After treatment, the observation group had obviously lower IgG, TRF and Alb than the control group, and the difference was statistically significant(P<0.05). The observation group had no statistically significant difference in incidence of adverse reactions as 14.29%, comparing with 9.52% in the control group(P>0.05). Conclusion Application of montelukast sodium for children with recurrent AP can effectively improve the urinary biochemical indicators and improve the clinical efficacy.

关 键 词：孟鲁司特钠 过敏性紫癜 小儿 

分 类 号：R725.5[医药卫生—儿科]